Aarti Drugs Limited (AARTIDRUGS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aarti Drugs Limited (AARTIDRUGS) has a cash flow conversion efficiency ratio of 0.104x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs1.52 Billion ≈ $16.48 Million USD) by net assets (Rs14.69 Billion ≈ $158.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aarti Drugs Limited - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Aarti Drugs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Aarti Drugs Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Aarti Drugs Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aarti Drugs Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DB Financial Investment Co Ltd
KO:016610
|
-0.116x |
|
Bhagiradha Chemicals & Industries Limited
NSE:BHAGCHEM
|
0.008x |
|
West Bancorporation
NASDAQ:WTBA
|
0.045x |
|
Bohai Water Industry Co Ltd
SHE:000605
|
0.008x |
|
Jiangsu Yuxing Film Tech
SHE:300305
|
0.058x |
|
Chongqing Sifang New Material Co. Ltd.
SHG:605122
|
N/A |
|
Shivalik Bimetal Controls Limited
NSE:SBCL
|
0.042x |
|
Thessaloniki Port Authority SA
AT:OLTH
|
0.031x |
Annual Cash Flow Conversion Efficiency for Aarti Drugs Limited (2007–2025)
The table below shows the annual cash flow conversion efficiency of Aarti Drugs Limited from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see AARTIDRUGS market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs13.69 Billion ≈ $148.09 Million |
Rs2.45 Billion ≈ $26.45 Million |
0.179x | -36.21% |
| 2024-03-31 | Rs12.82 Billion ≈ $138.64 Million |
Rs3.59 Billion ≈ $38.82 Million |
0.280x | +148.83% |
| 2023-03-31 | Rs11.93 Billion ≈ $128.98 Million |
Rs1.34 Billion ≈ $14.51 Million |
0.113x | +67.45% |
| 2022-03-31 | Rs10.36 Billion ≈ $112.07 Million |
Rs696.36 Million ≈ $7.53 Million |
0.067x | -60.36% |
| 2021-03-31 | Rs9.13 Billion ≈ $98.78 Million |
Rs1.55 Billion ≈ $16.75 Million |
0.170x | -55.88% |
| 2020-03-31 | Rs6.52 Billion ≈ $70.56 Million |
Rs2.51 Billion ≈ $27.12 Million |
0.384x | +45.95% |
| 2019-03-31 | Rs5.43 Billion ≈ $58.77 Million |
Rs1.43 Billion ≈ $15.47 Million |
0.263x | +71.88% |
| 2018-03-31 | Rs4.55 Billion ≈ $49.25 Million |
Rs697.66 Million ≈ $7.54 Million |
0.153x | -63.96% |
| 2017-03-31 | Rs4.11 Billion ≈ $44.42 Million |
Rs1.75 Billion ≈ $18.88 Million |
0.425x | +13.96% |
| 2016-03-31 | Rs3.57 Billion ≈ $38.65 Million |
Rs1.33 Billion ≈ $14.42 Million |
0.373x | +9.88% |
| 2015-03-31 | Rs3.08 Billion ≈ $33.33 Million |
Rs1.05 Billion ≈ $11.31 Million |
0.339x | -10.76% |
| 2014-03-31 | Rs2.51 Billion ≈ $27.13 Million |
Rs954.26 Million ≈ $10.32 Million |
0.380x | +6.26% |
| 2013-03-31 | Rs2.08 Billion ≈ $22.45 Million |
Rs743.10 Million ≈ $8.04 Million |
0.358x | +72.40% |
| 2012-03-31 | Rs1.76 Billion ≈ $19.09 Million |
Rs366.41 Million ≈ $3.96 Million |
0.208x | +64.76% |
| 2011-03-31 | Rs1.63 Billion ≈ $17.65 Million |
Rs205.60 Million ≈ $2.22 Million |
0.126x | -68.79% |
| 2010-03-31 | Rs1.46 Billion ≈ $15.84 Million |
Rs591.20 Million ≈ $6.39 Million |
0.404x | -18.58% |
| 2009-03-31 | Rs1.23 Billion ≈ $13.35 Million |
Rs612.10 Million ≈ $6.62 Million |
0.496x | +94.81% |
| 2008-03-31 | Rs1.12 Billion ≈ $12.06 Million |
Rs283.87 Million ≈ $3.07 Million |
0.255x | -12.94% |
| 2007-03-31 | Rs1.00 Billion ≈ $10.83 Million |
Rs292.69 Million ≈ $3.17 Million |
0.292x | -- |
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more